Latest news with #VagusNerve
Globe and Mail
19-03-2025
- Health
- Globe and Mail
Vagus Nerve Stimulators Market is Expected to Witness Positive Growth With A CAGR of 9.06% by 2030, estimates DelveInsight
"Vagus Nerve Stimulators Market" Vagus Nerve Stimulators companies are LivaNova, Soterix Medical Inc, MicroTransponder Inc, Parasym Ltd, electroCore, tVNS Technologies GmbH, and others. (Albany, USA) DelveInsight's Vagus Nerve Stimulators Market Insights report provides the current and forecast market, upcoming device innovation, individual leading companies market shares, challenges, market drivers, barriers, and trends, and key Vagus Nerve Stimulators companies in the market. As per DelveInsight analysis, the Vagus Nerve Stimulators Market is witnessing a surge primarily due to the rising prevalence of neurological diseases, the increasing popularity of VNS therapy as an alternative or even conjunctive treatment in cases where drug resistance develops, growing research in studying the effects of VNS on other indications, technological advancements leading to the development of new products such as non-invasive Vagus Nerve Stimulation devices, and others. Key Takeaways from the Global Vagus Nerve Stimulators Market According to DelveInsight analysis, North America is anticipated to dominate the global Vagus Nerve Stimulators market during the forecast period. The leading Vagus Nerve Stimulators companies such as LivaNova, Soterix Medical Inc, MicroTransponder Inc, Parasym Ltd, electroCore, tVNS Technologies GmbH, and others are currently dominating the Vagus Nerve Stimulators market. In February 2023, LivaNova PLC, a market-leading medical technology and innovation company, launched SenTiva DUO, an implantable pulse generator (IPG) with a dual-pin header to provide VNS Therapy for the treatment of drug-resistant epilepsy. In December 2022, electroCore, Inc., a commercial stage bioelectronic company, announced the launch of a new wellness product offering called Truvaga for customers residing in the U.S. In August 2021, the FDA approved the MicroTransponder Vivistim Paired VNS System, a one-of-its-kind, drug rehabilitation system with the intention to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke. In March 2020, LivaNova received the CE Mark approval for their Vagus Nerve Stimulation VNS Therapy® System, Symmetry™ for difficult-to-treat depression. For more insights about the Vagus Nerve Stimulators market; download the snapshot of the key highlights entailed in the Vagus Nerve Stimulators Market Report Vagus Nerve Stimulators A Vagus Nerve Stimulator is a pacemaker-like device that comes with an implantable programmable generator that is implanted in the chest wall and delivers electrical impulses to the vagus nerve in the neck thereby stimulating the vagus nerve and providing relief to patients. The FDA has approved an implantable vagus nerve stimulator to treat epilepsy and depression. In addition, in Europe, new non-invasive vagus nerve stimulation devices that do not require surgical implantation to treat epilepsy, depression, and pain have been approved. Vagus Nerve Stimulators Market Insights North America is estimated to account for the largest share in the Vagus Nerve Stimulation (VNS) devices market among all the regions. The key driving factors of the North America Vagus Nerve Stimulators market are the high prevalence of epilepsy, depression in the region, increasing disposable income, rising investments, and big collaborative expansions by key players in the region. Moreover, the conducive regulatory environment in the region is expected to establish the dominance of the North American Vagus Nerve Stimulation (VNS) devices market in the overall global landscape. Furthermore, advanced product launches and commercialization agreements among the key VNS companies are further expected to fuel the Vagus Nerve Stimulators market. For instance, in August 2021, the FDA approved drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke—a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms the first-of-its-kind Vagus Nerve Stimulation device the MicroTransponder Vivistim Paired VNS System. Thus, the interplay of all the aforementioned factors is likely to fuel the Vagus Nerve Stimulators market growth in the United States during the forecast period. Vagus Nerve Stimulators Market Dynamics The Vagus Nerve Stimulators market is experiencing an increase in product demand for a variety of reasons, with one of the key reasons being the rising prevalence of neurological disorders. Moreover, with more positive results being reported concerning the VNS therapy, more research is being conducted on different disease areas, which may further expand the application of Vagus Nerve Stimulation devices in the coming years. For instance, several studies are ongoing in studying the effects of VNS on tinnitus, irritable bowel syndrome, and chronic pain, among other indications. This further presents an opportunity for making significant headway in the Vagus Nerve Stimulators market in the near future. However, procedure-related complications and the high cost of these devices may be confining factors for the Vagus Nerve Stimulators market growth. Scope of the Vagus Nerve Stimulators Market Report Coverage: Global Study Period: 2022-2030 VNS Market Segmentation By Product Type- Invasive Vagus Nerve Stimulation Devices and Non-Invasive Vagus Nerve Stimulation Devices VNS Market Segmentation by Application- Migraine, Epilepsy, Depression, and Others VNS Market Segmentation By End-User - Hospitals, Specialty Clinics, and Others VNS Market Segmentation By Geography - North America, Europe, Asia-Pacific, and Rest of World Key Vagus Nerve Stimulators Companies - LivaNova, Soterix Medical Inc, MicroTransponder Inc, Parasym Ltd, electroCore, tVNS Technologies GmbH, and others. Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View DelveInsight Analysis: The Vagus Nerve Stimulators market is expected to grow at a CAGR of 9.06% during the forecast period (2024-30). Request to know more about Vagus Nerve Stimulators products and mechanism @ Vagus Nerve Stimulation Companies Table of Contents 1. Vagus Nerve Stimulators Market Report Introduction 2. Vagus Nerve Stimulators Market Executive summary 3. Regulatory and Patent Analysis 4. Vagus Nerve Stimulators Market Key Factors Analysis 5. Porter's Five Forces Analysis 6. COVID-19 Impact Analysis on Vagus Nerve Stimulators Market 7. Vagus Nerve Stimulators Market Layout 8. Vagus Nerve Stimulators Global Company Share Analysis – Key 3-5 Companies 9. Vagus Nerve Stimulators Market Company and Product Profiles 10. Project Approach About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Khaleej Times
13-03-2025
- Health
- Khaleej Times
Samitivej International Children's Hospital expands, advancing pediatric healthcare amidst rising medical tourism from the Gulf
Backed by a two billion THB ($58.9 million USD) investment, the expansion strengthens Samitivej's commitment to becoming Asia-Pacific's Leading Pediatric Referral Hub, providing specialised care, innovative treatments, and seamless medical coordination. The expansion comes as Thailand strengthens its position as a global healthcare destination, attracting patients from across Asia and the Middle East. According to Statista, Thailand's medical tourism industry was valued at 29 billion THB in 2023 (around $820 million USD), with an estimated 3.07 million international patients seeking specialized care. Families from the GCC - including Saudi Arabia, the UAE, Kuwait, Oman, and Qatar - continue to choose Thailand for comprehensive health check-ups, cardiology, oncology, and neonatal care, drawn by its internationally accredited hospitals and advanced medical expertise. Revolutionising pediatric care with advanced treatments Samitivej International Children's Hospital redefines pediatric excellence, offering cutting-edge treatments for complex and rare conditions, including: Open-Heart Surgery to Minimally Invasive Catheterisation – Complete heart care from birth, ensuring advanced treatment and faster recovery. Haploidentical Bone Marrow Transplant (BMT) to CAR-T Cell Therapy – Advanced treatments for blood disorders and cancer. Comprehensive Pediatric and Newborn Surgery – Expertise in performing procedures from head to toe, led by specialized doctors. Epilepsy Treatment with Medication to Vagus Nerve Stimulation (VNS) Implants – Solutions for drug-resistant epilepsy. Advancing Pediatric Excellence with Cutting-Edge Facilities The new eight-floor hospital features 111 beds, including 12 for critically ill children and 8 neonatal intensive care beds. It integrates Smart Hospital technology for efficiency and patient-centered care. Key features include: Hybrid Operating Room: Precision-driven newborn and pediatric surgical procedures using biplane imaging technology. World-Class Pediatric Specialties: Multidisciplinary teams treating complex and rare conditions. Advanced Neonatal and Pediatric Intensive Care: Specialised care for premature infants under 500 grams. Cutting-Edge Rehabilitation Center: Robotic-assisted gait training, Hybrid Assistive Limb (HAL) therapy, and Redcord NEURAC systems. Comprehensive International Patient Services: Pre-arrival teleconsultations, aeromedical transport, multilingual care teams, follow-up appointments, and medical evacuation and repatriation. Global partnerships and medical expertise As part of its commitment to delivering world-class pediatric healthcare, Samitivej collaborates with Doernbecher Children's Hospital (OHSU, USA) to enhance care for critically ill children, newborns, and trauma patients. A partnership with Takatsuki General Hospital (Japan) ensures specialised neonatal and allergy treatments, providing access to the latest pediatric advancements. Pioneering smart hospital innovations Samitivej leads in digital healthcare, integrating technology to enhance efficiency and patient care. Innovations include: Well Kidz App: Manages medical records, appointments, and remote consultations. Smart ER & Smart Ambulance Services: Real-time monitoring ensures rapid emergency response. Smart OPD & Smart IPD: AI-powered cost estimation, queue tracking, and seamless patient-medical team communication. D-Discharge System: Streamlined hospital discharge for greater convenience. Exceptional pediatric outcomes and achievements Samitivej delivers outstanding results: 7,000+ critical pediatric cases treated annually 1,000+ newborn and pediatric surgeries performed, including minimally invasive procedures 92% one-year survival rate for bone marrow transplants, surpassing global benchmarks 400+ newborns with heart conditions successfully treated through surgical correction Specialised care provided for premature infants with birth weights below 500 grams 98% trust rating from families A commitment to a healthier future for every child Dr Surangkana Techapaitoon, deputy CEO of Samitivej and BNH Hospitals and director of Samitivej International Children's Hospital, stated: "We want to see a healthier future for every child by integrating innovation, world-class expertise, and compassionate care. This facility strengthens our role as a leading pediatric referral hub, expanding access to specialised treatment and ensuring children everywhere receive the best care from infancy through adolescence." For more details, please visit:
Times of Oman
13-03-2025
- Health
- Times of Oman
Samitivej International Children's Hospital Expands, Advancing Pediatric Healthcare Amidst Rising Medical Tourism from the Gulf
Bangkok, Thailand: Samitivej Hospital, a leader in pediatric care, unveils its newly expanded standalone Samitivej International Children's Hospital at Samitivej Srinakarin Hospital in Bangkok. Backed by a 2 billion THB ($58.9 million USD) investment, the expansion strengthens Samitivej's commitment to becoming Asia-Pacific's Leading Pediatric Referral Hub, providing specialized care, innovative treatments, and seamless medical coordination. The expansion comes as Thailand strengthens its position as a global healthcare destination, attracting patients from across Asia and the Middle East. According to Statista, Thailand's medical tourism industry was valued at 29 billion THB in 2023 (around $820 million USD), with an estimated 3.07 million international patients seeking specialized care. Families from the GCC—including Saudi Arabia, the UAE, Kuwait, Oman, and Qatar—continue to choose Thailand for comprehensive health check-ups, cardiology, oncology, and neonatal care, drawn by its internationally accredited hospitals and advanced medical expertise. Revolutionizing Pediatric Care with Advanced Treatments Samitivej International Children's Hospital redefines pediatric excellence, offering cutting-edge treatments for complex and rare conditions, including: • Open-Heart Surgery to Minimally Invasive Catheterization – Complete heart care from birth, ensuring advanced treatment and faster recovery. • Haploidentical Bone Marrow Transplant (BMT) to CAR-T Cell Therapy – Advanced treatments for blood disorders and cancer. • Comprehensive Pediatric and Newborn Surgery – Expertise in performing procedures from head to toe, led by specialized doctors. • Epilepsy Treatment with Medication to Vagus Nerve Stimulation (VNS) Implants – Solutions for drug-resistant epilepsy. Advancing Pediatric Excellence with Cutting-Edge Facilities The new eight-floor hospital features 111 beds, including 12 for critically ill children and 8 neonatal intensive care beds. It integrates Smart Hospital technology for efficiency and patient-centered care. Key features include: • Hybrid Operating Room: Precision-driven newborn and pediatric surgical procedures using biplane imaging technology. • World-Class Pediatric Specialties: Multidisciplinary teams treating complex and rare conditions. • Advanced Neonatal & Pediatric Intensive Care: Specialized care for premature infants under 500 grams. • Cutting-Edge Rehabilitation Center: Robotic-assisted gait training, Hybrid Assistive Limb (HAL) therapy, and Redcord NEURAC systems. • Comprehensive International Patient Services: Pre-arrival teleconsultations, aeromedical transport, multilingual care teams, follow-up appointments, and medical evacuation and repatriation. Global Partnerships & Medical Expertise As part of its commitment to delivering world-class pediatric healthcare, Samitivej collaborates with Doernbecher Children's Hospital (OHSU, USA) to enhance care for critically ill children, newborns, and trauma patients. A partnership with Takatsuki General Hospital (Japan) ensures specialized neonatal and allergy treatments, providing access to the latest pediatric advancements. Pioneering Smart Hospital Innovations Samitivej leads in digital healthcare, integrating technology to enhance efficiency and patient care. Innovations include: • Well Kidz App: Manages medical records, appointments, and remote consultations. • Smart ER & Smart Ambulance Services: Real-time monitoring ensures rapid emergency response. • Smart OPD & Smart IPD: AI-powered cost estimation, queue tracking, and seamless patient medical team communication. • D-Discharge System: Streamlined hospital discharge for greater convenience. Exceptional Pediatric Outcomes & Achievements Samitivej delivers outstanding results: • 7,000+ critical pediatric cases treated annually • 1,000+ newborn and pediatric surgeries performed, including minimally invasive procedures • 92% one-year survival rate for bone marrow transplants, surpassing global benchmarks • 400+ newborns with heart conditions successfully treated through surgical correction • Specialized care provided for premature infants with birth weights below 500 grams • 98% trust rating from families A Commitment to a Healthier Future for Every Child Dr. Surangkana Techapaitoon, Deputy CEO of Samitivej and BNH Hospitals and Director of Samitivej International Children's Hospital, stated: 'We want to see a healthier future for every child by integrating innovation, world-class expertise, and compassionate care. This facility strengthens our role as a leading pediatric referral hub, expanding access to specialized treatment and ensuring children everywhere receive the best care from infancy through adolescence.'
Associated Press
06-03-2025
- Health
- Associated Press
Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System
Tivic Health ® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today new data that shows personalizing its non-invasive vagus nerve stimulation (ncVNS) method optimized the stimulation's impact on autonomic nervous system activity. Tivic Health believes these findings strongly support its strategy to develop highly personalized neuromodulation devices that can better address inflammatory, cardiac and neurologic disorders compared to current, more invasive treatment options. The data were presented in a poster presentation, titled, ' Autonomic, Cardiac, and Neural Effects from Non-Invasive Cervical Vagus Nerve Stimulation, ' at the Sixth Bioelectronic Medicine Summit, March 4 & 5. The findings were based on Tivic's collaboration with The Feinstein Institute of Medicine, one of the global scientific leaders in bioelectronic medicine. 'These promising findings reinforce Tivic's premise that non-invasive bioelectronic devices can effectively treat inflammatory, cardiac and neurologic disorders without invasive surgeries or pharmaceuticals - both of which carry burdensome side effects,' said Jennifer Ernst, CEO of Tivic Health. 'With these new data secured with pending patents, we believe that we have demonstrated the potential for developing personalized, scalable bioelectronic therapies to treat patients in need.' Tivic Health's poster presentation, titled, ' Autonomic, Cardiac, and Neural Effects from Non-Invasive Cervical Vagus Nerve Stimulation, ' highlighted a novel ncVNS approach and its ability to modulate autonomic nervous system (ANS) function and brain activity. Key results included: Personalized stimulation approach for optimal autonomic modulation: No single stimulation frequency had a universally dominant effect on HRV, highlighting the need for personalized neuromodulation strategies. Choosing the optimal ncVNS stimulation frequency for each study subject resulted in a meaningful increase in effect size of HRV change, paving the way for patient-specific therapy. Significant increase in heart rate variability (HRV), indicating enhanced parasympathetic activity: In 60% of participants (responders), raw HRV nearly doubled on average following ncVNS stimulation. Normalized HRV increased 2.67x post-stimulation, suggesting a strong activation of vagal tone and improved autonomic balance. The data presented resulted from Tivic's ongoing collaboration with the Feinstein Institute of Bioelectronic Medicine to advance high-precision vagus nerve stimulation in a non-invasive form factor. About The Bioelectronic Medicine (BEM) Summit The BEM Summit is a premier gathering of industry leaders, researchers, and clinicians exploring cutting-edge neurotechnologies and neuromodulation therapies. Hosted by the Feinstein Institutes for Medical Research, the event brings together experts in bioelectronic medicine, autonomic neuroscience, and inflammation research to discuss the latest advancements in the field. About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health. Tivic Health's bioelectronic division is developing non-invasive medical devices that personalize key stimulation parameters for the vagus nerve to deliver meaningfully improved effects on measures of the autonomous nervous system compared to current treatments, which are often invasive, ineffective or both. Tivic Health's biopharma division's lead product candidate is the TLR5 agonist, Entolimod™, which is in late-stage studies to treat acute radiation syndrome. The FDA has granted Fast Track and Orphan Drug designation to Entolimod™. Tivic Health already has an FDA-approved over-the-counter device, ClearUP™ that treats sinus pain and pressure and is available through online retailers and commercial distributors. For more information about Tivic Health, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of changes to the company's relationship with the Feinstein Institute, future development of the company's ncVNS treatment, changes to the company's business strategy, clinical trial and study results, consummation of any strategic transactions, the company's need for, and ability to secure when needed, additional working capital, and the company's ability to maintain its Nasdaq listing. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading 'Risk Factors'; as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law. Hanover International, Inc. SOURCE: Tivic Health Systems, Inc. Copyright Business Wire 2025. PUB: 03/06/2025 08:15 AM/DISC: 03/06/2025 08:17 AM
